Efficacy, safety, and biomarker analysis of datopotamab deruxtecan in advanced non-small cell lung cancer: ICARUS-LUNG01 phase 2 study

Cancer Cell · Published 2026-04-17 · DOI 10.1016/j.ccell.2026.03.017

Free full text

Authors being retrieved — see the publisher record. https://doi.org/10.1016/j.ccell.2026.03.017

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Related articles

• The next generation of antibody–drug conjugates · Nature Medicine · 2026 · Cites or is cited by this article
• Chronic stress unleashes an intratumor phage-fibroblast-B cell circuit to promote tumor growth · Cancer Cell · 2026 · Same journal
• Bridging clinical gaps in personalized cancer neoantigen vaccines · Cancer Cell · 2026 · Same journal
• When more target antigen expression is less · Cancer Cell · 2026 · Same journal
• Targeting drug-tolerant persister cells: Let’s bring on the TROPs! · Cancer Cell · 2026 · Same journal
• Dissecting the cellular architecture of breast cancer brain metastases reveals prognostically distinct immune landscapes · Cancer Cell · 2026 · Same journal
• Context dependency in cancer neuroscience · Cancer Cell · 2026 · Same journal
• A conserved re-epithelialization program underlies malignancy in pancreatic ductal adenocarcinoma · Cancer Cell · 2026 · Same journal
• Mapping cell type-resolved transcriptomic profiles to patient survival in pancreatic cancer · Cancer Cell · 2026 · Same journal
• Antibody-drug conjugates in precision oncology · Cancer Cell · 2026 · Same journal